Teva Debuts US Rituximab At A 10% Discount
Truxima Biosimilar Rival To Rituxan Is Licensed From Celltrion
Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.
You may also be interested in...
Amgen has received FDA approval and revealed launch plans for its Riabni rituximab rival to Rituxan, setting a price discount in line with Pfizer’s Ruxience version. However, the biosimilar has not been approved for the rheumatoid arthritis indication that is enjoyed by Teva and Celltrion’s higher-priced Truxima version.
Teva says the Truxima rituximab biosimilar it sells in the US in partnership with Celltrion has captured a fifth of the market a year after launch, driven in part by its exclusive rheumatoid arthritis indication.
In a busy second quarter for Teva, a COVID-19 slump acted as a correction to the related boost in demand seen in the first quarter of 2020.